Form D · Biotechnology
Good Therapeutics, Inc.
Seattle, WA · CIK 0001758604
Offering snapshot reported Dec 22, 2021 · SEC filing
- Reported sold
- $8.81M Offering amount: $26.4M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 8, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2021 | Initial | $8,813,099 | No comparison | 5 | SEC filing |
| May 21, 2020 | Amendment | $22,335,003 | $11,150,001vs Feb 8, 2019 | 6 | SEC filing |
| Feb 8, 2019 | Amendment | $11,185,002 | $5,150,000vs Nov 21, 2018 | 6 | SEC filing |
| Nov 21, 2018 | Initial | $6,035,002 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-426282
Source: Form D, filed Dec 22, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Karl Handelsman | Director |
| Diane Hollenbaugh | Executive |
| John Mc Kearn | Director |
| John Mulligan | Director, Executive, Promoter |
| Mitchell Mutz | Director |
| Neela Patel | Executive |
| Monique Schiersing | Director |
| Nicholas Walrod | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 Eastlake Avenue East, Suite 400
Seattle, WA, 98102
Seattle, WA, 98102